

## PUBLIC SUMMARY DOCUMENT

**Product:** Hollister VaPro Hydrophilic Intermittent Catheter

**Applicant:** Hollister

**Date of SPAP Meeting:** 22 October 2019

### 1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Hollister, sought listing of the Hollister VaPro Hydrophilic Intermittent Catheter in subgroup 8(c) of the Stoma Appliance Scheme (SAS) Schedule. The product, including seven variants, was proposed for listing at a unit price of \$2.980, with a maximum monthly quantity of 120 units.

### 2. Comparator

The applicant nominated Wellspect LoFric Hydrophilic Intermittent Catheters – Nelaton (SAS code 80184F) as the comparator. The product is currently listed in subgroup 8(c) of the SAS Schedule at the unit price of \$1.034, with a maximum monthly quantity of 120 units.

### 3. Background

This was the Stoma Product Assessment Panel's (SPAP) first consideration of this product.

### 4. Clinical Place for the Product

The proposed product is an alternative for users requiring an intermittent catheter.

### 5. SPAP Comment

#### *Clinical Analysis*

The Panel noted the VaPro Hydrophilic Intermittent Catheter is a touch-free hydrophilic intermittent catheter with a protective tip and sleeve.

The Panel also noted the applicant submitted data to support the application, however, the Panel agreed the data was insufficient, as it did not show a head to head study with the comparator product upon which a cost effectiveness analysis could be made. Therefore, the Panel agreed there was no justification for a Price Premium per unit price over the comparator product.

The Panel also noted the applicant requested a restriction for 'those who are at risk', however, the Panel noted this restriction was too broad and difficult to monitor and could potentially apply to any patient.

The Panel encourages the supplier to discuss with the Department the evidence requirements for an application requesting a price premium over the comparator.

#### *Economic Analysis*

Not undertaken.

#### *Financial Analysis*

Not undertaken

## **6. SPAP Recommendation**

The SPAP recommended that the application to list the Hollister VaPro Hydrophilic Intermittent Catheter, including seven variants in subgroup 8(c), be rejected due to insufficient evidence to support a Price Premium per unit price over the comparator.

## **7. Context for Decision**

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

## **8. Applicant's Comment**

Hollister accepts the SPAP's recommendation.